1. CMR Factbook

   Yearly publication of reliable, authoritative pharmaceutical performance metrics and trends analysis from CMR International.

2. Newport for Generics – Premium, Global, and Sourcing packages

   By incorporating the unique strategic intelligence and powerful competitive analysis that is only available from Thomson Reuters, we help you be first to find the drug, first to find the niche, first to make the deal, and first to get to market.

3. Newport for Innovators – Premium, Global, and Sourcing packages

   If you’re an innovator, we can give you up to seven years’ advance warning of generic product development activities, patent challenges and attempts at patent circumvention. Our powerful competitive intelligence and analytical tools can help you identify, assess and track the earliest signs of generic competition.

4. Newport Generic Deals Module

   The Newport Generic Deals Module covers many thousands of merger, acquisition, development, supply, manufacturing, joint venture, patent settlement and authorized generic deals involving generic companies worldwide since 1999.

5. Newport Phase III Drugs Module

   The Newport Phase III Drugs Module extends the coverage of APIs from approved and/or launched drugs to include more than 400 compounds in late stage development (Phase III clinical, registration or under review).